Evopoint Biosciences Overview
- Year Founded
-
2017
- Status
-
Public
- Employees
-
50
- Stock Symbol
-
688837
- Investments
-
1
- Share Price
-
$4.71
- (As of Thursday Closing)
Evopoint Biosciences General Information
Description
Evopoint Biosciences Co Ltd is a biopharmaceutical company engaged in the research, development, and commercialization of drugs.
Contact Information
Website
www.evopointbio.comCorporate Office
- Building 22, Phase II, Bio-industry Park
- Number 218 Sangtian Road
- Suzhou, Jiangsu 215000
- China
Corporate Office
- Building 22, Phase II, Bio-industry Park
- Number 218 Sangtian Road
- Suzhou, Jiangsu 215000
- China
Evopoint Biosciences Stock Performance
As of 19-Nov-2026, Evopoint Biosciences’s stock price is $4.71. Its current market cap is $2.05B with 435M shares.
(As of Thursday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $4.71 | $4.94 | $4.69 - $11.77 | $2.05B | 435M | 11M | -$0.18 |
Evopoint Biosciences Financials Summary
As of 30-Sep-2026, Evopoint Biosciences has a trailing 12-month revenue of $34.1M.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 3,255,514 | |||
| Revenue | 34,057 | 130,052 | 0 | 0 |
| EBITDA | (60,421) | 49,036 | (48,339) | (57,105) |
| Net Income | (65,746) | 28,167 | (53,794) | (60,338) |
| Total Assets | 538,413 | 249,087 | 149,078 | 160,336 |
| Total Debt | 196,651 | 128,382 | 71,434 | 58,153 |
Evopoint Biosciences Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Evopoint Biosciences Patents
Evopoint Biosciences Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026189357-A1 | Pharmaceutical composition comprising β-lactamase inhibitor and use thereof | Pending | 10-Mar-2025 | ||
| WO-2026171195-A1 | Pharmaceutical composition comprising piperidine ring compound, and use thereof | Pending | 12-Feb-2025 | ||
| WO-2026153068-A1 | Dihydropyrazolopyridinone compound and use thereof | Pending | 14-Jan-2025 | ||
| WO-2026145506-A1 | Pharmaceutical composition comprising polysubstituted benzene ring compound, and use method therefor | Pending | 30-Dec-2024 | ||
| WO-2026086944-A1 | Aminopyridone macrolide compound and use thereof | Pending | 24-Oct-2024 | C07H17/00 |
Evopoint Biosciences Signals
Evopoint Biosciences Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Evopoint Biosciences Investments (1)
Evopoint Biosciences’s most recent deal was a Early Stage VC with MediLink Therapeutics. The deal was made on 13-Dec-2020.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| MediLink Therapeutics | 13-Dec-2020 | Early Stage VC | Drug Discovery |
Evopoint Biosciences FAQs
-
When was Evopoint Biosciences founded?
Evopoint Biosciences was founded in 2017.
-
Where is Evopoint Biosciences headquartered?
Evopoint Biosciences is headquartered in Suzhou, China.
-
What is the size of Evopoint Biosciences?
Evopoint Biosciences has 50 total employees.
-
What industry is Evopoint Biosciences in?
Evopoint Biosciences’s primary industry is Drug Discovery.
-
Is Evopoint Biosciences a private or public company?
Evopoint Biosciences is a Public company.
-
What is Evopoint Biosciences’s stock symbol?
The ticker symbol for Evopoint Biosciences is 688837.
-
What is the current stock price of Evopoint Biosciences?
As of 19-Nov-2026 the stock price of Evopoint Biosciences is $4.71.
-
What is the current market cap of Evopoint Biosciences?
The current market capitalization of Evopoint Biosciences is $2.05B.
-
What is Evopoint Biosciences’s current revenue?
The trailing twelve month revenue for Evopoint Biosciences is $34.1M.
-
What is Evopoint Biosciences’s annual earnings per share (EPS)?
Evopoint Biosciences’s EPS for 12 months was -$0.18.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process